文献速递肿瘤 PET/CT核素与放射性配体治疗

82Rb PET/CT 定量肿瘤灌注成像在前列腺癌中的分析与临床验证

Quantitative Tumor Perfusion Imaging with 82Rb PET/CT in Prostate Cancer: Analytic and Clinical Validation.
PubMed 文献 · J Nucl Med · 2019-01-25

本研究评估 82Rb PET/CT 作为前列腺癌定量肿瘤血流成像工具的价值。研究1以 15O-H2O PET 为参考,显示 82Rb K1 和 SUV 与肿瘤血流量强相关。研究2显示前列腺癌 82Rb SUV 显著高于正常前列腺且无重叠,提示其可用于评估肿瘤侵袭性。

要点

  • 82Rb K1 和 SUV 与 15O-H2O PET 测得的肿瘤血流量强相关。
  • 前列腺癌 82Rb SUV 显著高于正常前列腺组织,两组无重叠。
  • 82Rb SUV 与根治性前列腺切除术后 Gleason 分级分组相关。

核心结论

  • 82Rb PET/CT 可用于前列腺癌肿瘤血流量定量,简单 SUV 即可估算血流量。
  • 82Rb 摄取在前列腺癌中显著高于正常前列腺组织,无重叠,验证了临床试验主要假设。
  • 82Rb SUV 与根治性前列腺切除术后 Gleason 分级分组相关,提示与癌症侵袭性有关。

研究设计与样本

  • 研究1纳入 9 例计划行根治性前列腺切除术的前列腺癌患者,行前列腺多参数 MRI 及心脏和盆腔 15O-H2O PET 与 82Rb PET,并与术后 Gleason 分级分组比较。
  • 研究2为临床试验(EudraCT 2016-003185-26),纳入 15 例原发性高危前列腺癌患者和 12 例无已知前列腺疾病的对照者,行盆腔 82Rb PET,前列腺癌患者另有 68Ga-PSMA PET/CT。

主要发现

  • 研究1中 82Rb K1 与 15O-H2O 肿瘤血流量强相关(ρ=0.95,P<0.001),82Rb SUV 亦相关(ρ=0.77,P=0.015)。
  • 研究1中 82Rb SUV 与 K1 线性相关(r=0.92,P=0.001),82Rb SUV 与术后 Gleason 分级分组相关(ρ=0.70,P=0.03)。
  • 研究2中前列腺癌 82Rb SUV 为 3.19±0.48,显著高于健康对照正常前列腺的 1.68±0.37(P<0.001),两组间无重叠。

关键数值与推荐

  • 研究1中 82Rb K1 与 15O-H2O 肿瘤血流量的相关系数 ρ=0.95(P<0.001),82Rb SUV 的相关系数 ρ=0.77(P=0.015)。
  • 研究1中 82Rb SUV 与 K1 的相关系数 r=0.92(P=0.001),82Rb SUV 与术后 Gleason 分级分组的相关系数 ρ=0.70(P=0.03)。
  • 研究2中前列腺癌 82Rb SUV 为 3.19±0.48,健康对照正常前列腺为 1.68±0.37,组间比较 P<0.001。

临床怎么用

  • 82Rb PET/CT 有潜力作为无创工具评估非转移性前列腺癌的肿瘤侵袭性并进行监测。
  • 简单 SUV 即可估算肿瘤血流量,便于临床推广应用。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The aim of this work was to evaluate 82Rb PET/CT as a diagnostic tool for quantitative tumor blood flow (TBF) imaging in prostate cancer (PCa). Study 1 was performed to evaluate 82Rb as a marker of TBF, using 15O-H2O PET as a reference method. Study 2 investigated the ability of 82Rb uptake measurements to differentiate between PCa and normal prostate. Methods: Study 1: 9 PCa patients scheduled for radical prostatectomy were included. Prostate multiparametric MRI and both cardiac and pelvic 15O-H2O PET and 82Rb PET were performed. PET findings were compared with postprostatectomy Gleason grade group (GGG). Study 2: 15 primary high-risk PCa patients and 12 controls without known prostate disease were included in a clinical drug trial (EudraCT 2016-003185-26). 68Ga-prostate-specific membrane antigen PET/CT scans of PCa patients were available. Pelvic 82Rb PET was performed. Results: Study 1: both 82Rb K1 and 82Rb SUVs correlated strongly with 15O-H2O TBF (ρ = 0.95, P < 0.001, and ρ = 0.77, P = 0.015, respectively). 82Rb SUV and K1 were linearly correlated (r = 0.92, P = 0.001). 82Rb SUV correlated with postprostatectomy GGG (ρ = 0.70, P = 0.03). Study 2: 82Rb SUV in PCa (3.19 ± 0.48) was significantly higher than prostate 82Rb SUV in healthy controls (1.68 ± 0.37) (P < 0.001), with no overlap between groups. Conclusion: Study 1 shows that 82Rb PET/CT can be used for TBF quantification and that TBF can be estimated by simple SUV and suggests that 82Rb SUV is associated with postprostatectomy GGG and, hence, cancer aggressiveness. Study 2 shows that 82Rb uptake is significantly higher in PCa than in normal prostate tissue with no overlap between cohorts, confirming the primary hypothesis of the clinical trial. Consequently, 82Rb PET/CT may have potential as a noninvasive tool for evaluation of tumor aggressiveness and monitoring in nonmetastatic PCa.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Jochumsen MR, Tolbod LP, Pedersen BG, et al. Quantitative Tumor Perfusion Imaging with 82Rb PET/CT in Prostate Cancer: Analytic and Clinical Validation. J Nucl Med. 2019. PMID: 30683762. doi:10.2967/jnumed.118.219188

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。